Diabetes News

In this video, Ralph A. DeFronzo, MD, discusses the potential of new drugs in the cardiovascular and endocrinology specialties to help slow progression of cardiometabolic disorders for people with diabetes and chronic kidney disease.

In this video perspective, Ian de Boer, MD, MS, discusses the connection between chronic kidney disease and cardiometabolic disease.

In this video perspective, internist Pamela Kushner, MD, FAAFP, discusses how cognitive impairment can impact a patient’s ability to understand their health care needs.

In this video perspective, George L. Bakris, MD, discusses the long-term influence of hypertension on patients with chronic kidney disease.

Patients with prediabetes who participated in shared medical appointments lost more weight and experienced greater reductions in HbA1C and BP levels than their counterparts who received usual care, a retrospective cohort study showed.

The dual SGLT1/SGLT2 inhibitor sotagliflozin is effective at reducing risk for heart failure, myocardial infarction and stroke while also slowing progression of chronic kidney disease, according to findings from two large clinical trials.

A novel GLP-1 receptor agonist reduced cardiovascular event risk by 27% and kidney disease progression by 32% compared with placebo for high-risk adults with type 2 diabetes, with or without background SGLT2 inhibitor therapy, data show.

A dental intervention among patients with type 2 diabetes improved their oral health-related quality of life, a pilot study in the Netherlands showed.

Sotagliflozin increased the number of days alive and out of the hospital compared with placebo among patients with type 2 diabetes at high risk for intermittent hospitalization due to worsening heart failure, data show.

A group of leading experts in cardiology, endocrinology and nephrology will gather for a workshop to discuss best practices for managing diabetes with cardiorenal metabolic diseases, with the goal of creating a new consensus statement.